Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01410526 |
| Other study ID # |
1354_9/5/2011 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 2011 |
| Est. completion date |
August 2015 |
Study information
| Verified date |
August 2021 |
| Source |
Aristotle University Of Thessaloniki |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Protocol Synopsis
Protocol title: Assessment of peritoneal immune response in patients with severe
intra-abdominal sepsis managed by laparostomy and VAC
Purpose: Assessment of peritoneal immune response in patients with severe intra-abdominal
sepsis
Design: Prospective, single-center study
Patient Population: Male or female adults (>18 years) with severe intra-abdominal sepsis
No. of Subjects: 60 patients divided into two groups, 30 patients with severe intra-operative
sepsis and 30 patients without sepsis scheduled to undergo major abdominal operations (middle
line incision>15cm). The study is estimated up to 2 year to enroll
Duration of Follow-up: Follow-up will be performed daily while hospitalized, until patient
discharged or deceased.
Endpoints:
1. To measure the peritoneal cytokines levels in patients with severe intra-abdominal
sepsis.
2. To correlate the cytokines levels in the abdominal cavity and the serum plasma.
3. To correlate cytokines response in serum plasma and peritoneal fluid with mortality and
morbidity.
4. To compare cytokines results in serum plasma and peritoneal fluid between patients with
severe intra-abdominal sepsis and patients undergoing major laparotomy without sepsis.
5. To assess the microbial load in the abdominal cavity in patients with severe sepsis.
6. To assess the biofilm formation in VAC polyurethane sponge.
Description:
Principal Investigator Statement: ……………………………………………… 1 Protocol Synopsis:
……………………………………………………………… 2 Table of Content: ………………………………………………………………. .4 1.0 Introduction:
……………………………………………………………. 5 2.0 Techniques descriptions: ……………………………..………………… 6 3.0
Objectives: ……………………………..…………………………………7 4.0 Design and study population: …………………………………………… 7
5.0 Study procedure: ……………………………..………………………… 8 6.0 Complications and adverse events:
…………………………………… 15 7.0 Statistical analysis: ……………………………..……………………… 15 8.0 Data monitoring
plan: ……………………………..………………… 16 9.0 Data confidentiality: ……………………………..…………………… 16 10.0
Funding: ……………………………..………………………………… 16 11.0 Ethics: ……………………………..…………………………………… 16 12.0
Informed consent: ……….……………………………..………………. 17 13.0 References: ……………………………………..……………………… 18
1.0 INTRODUCTION
Severe abdominal sepsis is defined as sepsis plus organ dysfunction caused by a condition
deriving from the peritoneal cavity [1]. The essentials of the management of patients with
severe sepsis remain unchanged and can be divided broadly into sepsis control, antimicrobial
therapy and hemodynamic stabilization [2]. Infection control mainly involves surgical
exploration and temporary or permanent resolution of the septic agent [3]. Open abdomen
treatment remains one of the most valid approaches of patients with severe abdominal sepsis
[4]. Open abdomen management is mandated to avoid abdominal compartment syndrome, in cases
with inability to re-approximate the abdominal fascia regardless to viscera oedema and
intra-abdominal pressure and in cases with unclear or inadequate source control [5]. Topical
negative pressure with the abdominal vacuum-assisted closure (VAC) device has been
introduced, providing a new option to manage an open abdomen [6-8].
Cytokines are a group of proteins produced by a variety of cells playing an active role in
the immune system. Sepsis syndrome seems to result from overwhelming systemic inflammation
which is caused by excessive release of cytokines into systemic circulation [9]. During the
last decade many clinical studies assess the cytokines concentration in serum plasma in
patients with SIRS and sepsis [10-13]. Despite the board study and analysis of cytokines
response in serum plasma, literature is poor about peritoneum immune response in
intra-abdominal sepsis [14-15], whereas the majority of these studies concerned patients with
elective surgery [16-18].
This protocol is designed to assess the cytokines levels in the peritoneal cavity in severe
intra-abdominal sepsis and to compare these levels with the corresponding values in serum
plasma. Additionally, the cytokines values in serum plasma and peritoneum are compared
between patients with and without sepsis that underwent major elective laparotomy (middle
line incision >15cm). Moreover, cytokines levels are correlated to morbidity and mortality.
2.0 STUDY PROTOCOL In all patients that the origin of sepsis confirmed pre-operative as
abdominal, laparotomy will be required. After incision and confirmation of intra-abdominal
sepsis, involving the whole peritoneal cavity, peritoneal fluid will be sampled for
microbiology culture and cytokines assessment. The appropriate source control interventions
will be made and peritoneal lavage will be performed using sterile isotonic sodium chloride
solution. At the end of operation a decision for open abdomen will be made by the surgeon,
based on the severity of sepsis. If laparostomy will be decided, temporary abdominal closure
will be performed with the Vacuum Assisted Closure (VAC) system plus the dynamic sutures
[19].
After a two-day application of the VAC, the previous existing dressing will be removed.
Peritoneal fluid samples and blood samples will be obtained for cytokines assessment. The
abdominal cavity will carefully be rinsed with saline solution and the various abdominal
spaces will be inspected for any collections. Additionally, peritoneal fluid sample will be
obtained for culture and quantitive analysis. Sequentially, the VAC dressing application will
be performed based on previously described protocol [19]. Patients will return to the
operating room for sequential fascial closure and replacement of the sponge and sutures every
2 days until the final open abdomen closure. Peritoneal fluid and blood serum samples will be
obtained in every VAC change until the permanent abdominal closure or patient's decease. A
piece of polyurethane sponge of VAC system will be sent to microbiology department for
detection of biofilm formation.
3.0 OBJECTIVES
1. To assess the cytokines in peritoneal fluid in patients with severe intra-abdominal
sepsis.
2. To compare the serum plasma cytokines values in patients with severe intra-abdominal
sepsis with the corresponding values in the peritoneal fluid.
3. To compare the cytokines values in serum plasma and peritoneal fluid between patients
with severe intra-abdominal sepsis and patients without sepsis underwent major elective
laparotomy.
4. To evaluate parameters influencing successful, primary abdominal closure, morbidity and
mortality.
5. To assess the microbial load in the abdominal cavity in patients with severe sepsis.
6. To assess the biofilm formation in VAC polyurethane sponge.
4.0 DESIGN AND STUDY POPULATION The study is designed as a prospective single center study.
Any patient with sepsis suspected pre-operative to be from abdominal origin that will be
needed laparotomy and postoperative laparostomy will be assessed.
Control group will be constituted with patients without sepsis that will be underwent major
elective laparotomy.
4.1 Inclusion Criteria
1. Patient > 18 years old
2. 30 patients with severe abdominal sepsis in order to form the study group and 30
patients without sepsis undergoing major elective surgery (middle line incision >15cm)
to form the control group.
3. Patient or relatives signs and dates a written informed consent form (ICF) and indicates
an understanding of the study procedures
4.2 Exclusion Criteria
1. Patient's Manheim Peritonitis Score < 29
2. Patient's pre-operative SOFA score < 6
3. The use of other temporary abdominal closure system
4. Decease before the first VAC dressing change
5. Patient is participating in another clinical trial which may affect this study's
outcomes
6. Patients with immune deficiency
7. Documented seropositivity for human immunodeficiency virus (AIDS)
8. Patient receiving steroids treatment for other medical condition
9. Patient receiving chronic anti-inflammatory treatment
10. Patient receiving anti- TNF treatment
11. Pre-existing parechymal liver disease ( Cirrhosis - Child-Pugh C)
12. Pregnancy
4.3 Duration of the study The study will be conducted until 30 patients of each group are
treated. It is estimated that it will take up to 2 year to enroll the patients.
5.0 STUDY GROUP PROCEDURES
5.1 Pre-Surgery
The following pre-surgery information will be recorded:
1. Demographic information including: Date of birth (age), gender, ethnicity
2. Pre-operative duration of sepsis - symptoms
3. Co-morbidities
4. BMI
5. ASA score
6. SOFA score
7. APACHEII score
8. Intra-abdominal pressure (IAP)
9. Preoperative labs (WBC, Ht, Hb, SGOT, SGPT, LDH, Glu, Ure, Cre, K+, Na+, Ca2+, Mg++, TP,
Alb, ALP, γ-GT, Amylase)
10. Coagulation (Fibrinogen, PT, aPTT, INR)
11. CRP, PCT, Lectin Binding Protein (LBP)
12. Ischemia Modulated Albumine (IMA)
13. Pre-operative Diagnosis
14. Medications
15. Current and past history of surgical and medical comorbidities
16. Measurement in blood serum plasma sample: IL 1α, IL 1β, IL6, IL8, IL12, IL 10, IL 18,
INF-γ, TNF-α, PGF-B, PAF, FGF-β, C5q, C3q, ICAM-I (CD54).
17. Measurement in blood serum plasma sample: fractalkine, CCL6.
5.2 Intra-operative
The surgeon will perform laparotomy and intra-operative sepsis source control. Peritoneal
fluid sample will be obtained for culture. Assessment of intra-peritoneal sepsis will be
performed and decision for open abdomen management will be made. At the end of the surgery,
peritoneal and blood samples will be obtained for cytokines measurement. The following
intraoperative variables will be recorded for all patients:
1. Surgery date
2. Operation
3. Manheim Peritonitis Score (MPS)
4. Peritonitis classification (a. fecal peritonitis b. purulent peritonitis, c. necrotizing
Pancreatitis, d. postoperative peritonitis, e. necrotizing fasciitis)
5. Procedure relative comments
6. Technical complications
7. Duration of surgery
8. Difficulty of the operation (1=very difficult to 5=very easy)
9. Peritoneal fluid culture
10. Blood serum sample (at closure): (WBC, Ht, Hb, SGOT, SGPT, LDH, Glu, Ure, Cre, K+, Na+,
Ca2+, Mg++, TP, Alb, ALP, γ-GT, Amylase, Fibrinogen, PT, aPTT, INR, CRP, PCT, LBP)
11. Blood serum sample (at closure): IL 1α, IL 1β, IL6, IL8, IL12, IL 10, IL 18, INF-γ,
TNF-α, PGF-B, PAF, FGF-β, C5q, C3q, ICAM-I (CD54), spectalkine, CCL6.
12. Peritoneal sample (at closure): IL 1α, IL 1β, IL8, IL12, IL 10, IL 18, INF-γ, TNF-α,
PGF-B, PAF, FGF-β, C5q, C3q, ICAM-I (CD54), spectalkine, CCL6.
5.3 Admission at Intensive Care Unit (ICU)
1. SOFA Score
2. APACHEII Score
3. Blood serum sample: (WBC, Ht, Hb, SGOT, SGPT, LDH, Glu, Ure, Cre, K+, Na+, Ca2+, Mg++,
TP, Alb, ALP, γ-GT, Amylase, Fibrinogen, PT, aPTT, INR, CRP, PCT, LBP)
5.4 Postoperative follow-up
Follow-up evaluation will be performed in every VAC dressing changes while hospitalized in
ICU until laparostomy final closure or patient decease. The following information will be
recorded for all patients in every change:
1. Assessment of peritoneal cavity
2. Sofa score
3. Peritoneal fluid culture
4. blood serum sample (at change): (WBC, Ht, Hb, SGOT, SGPT, LDH, Glu, Ure, Cre, K+, Na+,
Ca2+, Mg++, TP, Alb, ALP, γ-GT, Amylase, Fibrinogen, PT, aPTT, INR, CRP, PCT, LBP)
5. blood serum sample (at change): IL 1α, IL 1β, IL6, IL8, IL12, IL 10, IL 18, INF-γ,
TNF-α, PGF-B, PAF, FGF-β, C5q, C3q, ICAM-I (CD54), spectalkine, CCL6.
6. Peritoneal sample (at change): IL 1α, IL 1β, IL6, IL8, IL12, IL 10, IL 18, INF-γ, TNF-α,
PGF-B, PAF, FGF-β, C5q, C3q, ICAM-I (CD54), spectalkine, CCL6.
7. Re- operations:
8. Date of re-operation:
9. Re-procedure description :
10. Date of permanent abdominal wall closure:
11. Successful primary abdominal closure: YES NO
12. Type of closure:
13. Duration of open abdomen:
14. Number of VAC dressing changes:
15. Death: YES NO
16. Date of death:
17. Duration of ICU stay:
18. Date of ICU discharge:
19. Duration of hospitalization:
20. Date of discharge:
21. Final patient outcome:
22. Comments
5.5 Blood and peritoneal fluid sampling protocol Blood sample will draw from an indwelling
arterial line (10ml) in every VAC dressing change. Aspiration of 5 ml of peritoneal fluid
from the Douglas space will be carried out with a syringe prior the lavage. Blood samples
allow clotting in glass tubes in room temperature. Peritoneal sample collect in glass tubes.
Both blood and peritoneal samples will be centrifuged and the resulting serum will be stored
at -70o until processing.
5.6 Bacteriological sampling and cultures At initial explorative laparotomy an aspiration of
5 ml of fluid from the Douglas space will be carried out with a syringe. The sample will be
emptied into a rubber membrane-sealed sterile glass tube and will be transported immediately
to the laboratory, where it will be directly processed. The same process will be repeated at
each change of dressings. Moreover, in every VAC dressing change a piece of the polyurethane
sponge will be sent in the microbiology department for detection of biofilm formation.
5.7 Antimicrobic prophylactic regime According to the Greek national guidelines for the
antimicrobic therapy, a second generation cephalosporin (750 mg) combined with metronidazole
(500 mg) will be empirically used against community acquired peritonitis, 30 minutes prior to
induction of anaesthesia. Against postoperative peritonitis, piperacillin-tazobactam (4.5 g)
will be employed. The antibiotic schema will be later adjusted according to the peritoneal
fluid culture.
5.8 Control group Thirty patients without sepsis scheduled for major elective surgery will
constitute the control group. Blood sample and peritoneal fluid sample will be obtained at
the end of operation before abdominal closure. Subsequently, blood samples will be obtained
at first and third postoperative day for serum plasma cytokines assessment.
Inclusion criteria:
1. Patient is over 18 years old
2. Patient or relatives signs and dates a written informed consent form (ICF) and indicates
an understanding of the study procedures
Exclusion criteria:
1. Patient is participating in another clinical trial which may affect this study's
outcomes
2. Patients with immune deficiency
3. Documented seropositivity for human immunodeficiency virus (AIDS)
4. Patient receiving steroids treatment for other medical condition
5. Pre-existing parechymal liver disease ( Cirrhosis - Child-Pugh C)
6. Pregnancy
6.0 COMPLICATIONS AND ADVERSE EVENTS The coordinator is required to notify the Ethics
Committee according to regulations and requirements.
Serious Adverse Events include:
1. Death regardless of cause
2. Any-life-threatening event
3. Any re-hospitalization or prolongation of existing hospitalization
4. Any event that results in persistent or significant disability or incapacity to the
patient.
7.0 STATISTICAL ANALYSIS The objective of this study is: a) to assess the peritoneal immune
response in patients with severe intra-abdominal sepsis, b) to compare the serum plasma
cytokines values in patients with severe intra-abdominal sepsis with the corresponding values
in the peritoneal fluid and c) to compare the cytokines values in serum plasma and peritoneal
fluid between patients with severe intra-abdominal sepsis and patients without sepsis
underwent major elective laparotomy.
Statistical analysis included description of these pre-operative intraoperative and
postoperative outcomes, and indication of patient characteristics associated with these
outcomes.
In order to efficiently compare the results in patients with severe intra-abdominal sepsis, a
control group without sepsis underwent major abdominal surgery was employed (Group A=sepsis
and Group B=elective surgery).
Since the study does not have pre-specified hypotheses all statistical analyses are
exploratory and interpretation of results should be within this context.
8.0 DATA MONITORING PLAN The coordinator will monitor all data accrual. Furthermore, the
coordinator will review the progress of the clinical trial including safety data and ensure
as possible that it is conducted, recorded and reported in accordance with the protocol, good
clinical practice and the applicable regulatory requirements.
9.0 DATA CONFIDENTIALITY Each patient ill be identified by his/her initials and a unique
patient identification number. Source data will be stored with source documents. Only
personnel responsible for collecting data and transcribing it into the case report forms will
have access to the data. Records will remain on site in secure areas.
10.0 FUNDING No additional funding for the execution of the present protocol is necessary.
The investigators are willing to execute the present study without any additional
reimbursement.
11.0 ETHICS Prior to study institution review board (IRB) approval should be obtained. Any
changes in the study protocol, informed consent forms, or investigator must be re-approved by
the IRB. All patients enrolled in the study will provide their consent prior to entering the
study. An informed consent form shall be signed and dated by the patient. The investigator
will retain the forms as part of the study records.
This study will be executed in accordance with the Declaration of Helsinki, in agreement with
the guidelines for conducting a clinical investigation in accordance with the principles of
ICH GCP outlined in the E6 document. By signing the present protocol, participants in the
study commit themselves to carry it out in accordance with local legal requirements.
12.0 INFORMED CONSENT
All eligible patients or the closest relatives should have the capacity to provide an
informed consent.
The above described inclusion and exclusion criteria were designed to ensure the entry of the
appropriate population of patients to this study and will be approved by the local IRB.
Screening for these criteria will be conducted by the coordinator.
Eligible patients or the closest relatives will be educated about the research proposal by a
study investigator. To determine whether the patient or the relatives has understood the
issues, he/she will be asked to describe what the research entails and whether they have any
questions. All questions will be addressed prior to enrolment. The patient or his legal
representative can refuse participation in the study at any time.
A written informed consent form will be generated. For each patient, a case report form (CRF)
will be completed, providing general medical information and history.
